A persistent misconception in cross-border cell therapy is that Mainland China categorically prohibits human cells or tissue from crossing its border. That shorthand is too broad and, in many cases, misleading. The applicable rules depend on what is moving—a finished therapy, patient-derived starting material, a diagnostic sample or research material—together with its origin, purpose and intended place of use. Understanding these distinctions is essential to determining whether a Mainland China, Greater Bay Area, Macau or Singapore access strategy is legally and operationally viable.
The short answer
Only in defined circumstances. Mainland China does not impose a single, blanket prohibition on every cross-border movement of human cells, tissue or other biological materials. It does, however, impose substantial category-specific restrictions. A particular movement may require prior approval, filing, Customs inspection or other controls—and some proposed pathways may not be legally available at all.
The applicable rules depend principally on four questions:
- What is crossing the border: a finished therapy, starting material, diagnostic sample or research material?
- Does it involve Chinese-origin human genetic resources?
- Is the purpose clinical treatment, manufacturing, testing or research?
- Where will collection, processing and administration occur: Mainland China, Hong Kong, Macau, Singapore or elsewhere?
These are separate regulatory issues. A finished cell-therapy product generally cannot be imported and administered in Mainland China unless it has the necessary Mainland authorization or qualifies for a specific lawful access pathway. Sending collected patient cells abroad may engage human genetic resources, Customs, biosafety, data-protection, transport and destination-country requirements. A patient traveling to another jurisdiction for treatment is a different regulatory event, but the therapy, treating institution and patient-specific use must still be lawful in that jurisdiction.
Importing a finished cell therapy into Mainland China
A cell-therapy product regulated as a drug cannot enter Mainland clinical use merely because human cells are legally capable of crossing the border.
Under the PRC Drug Administration Law, imported drugs generally require the appropriate regulatory authorization and import procedures. A medical institution may apply to import a small quantity of an urgently needed drug for a specified institutional and clinical purpose, but this is a controlled exception—not a general commercial supply route. (PRC Drug Administration Law)
China Customs’ revised rules for inbound and outbound special articles, issued under General Administration of Customs Order No. 281 and effective from August 1, 2026, expressly cover human tissue, blood, cells and certain other biological materials.
However, goods already regulated as drugs, medical devices or veterinary drugs are excluded from that particular special-articles framework and instead follow their respective regulatory regimes. (Customs Order No. 281; official Customs interpretation)
That distinction is crucial. Exclusion from the Customs special-articles framework does not mean a cell-therapy drug can enter Mainland China without approval. It means the product must be assessed under the applicable drug rules instead.
Patient travel is not the same as product import
If a patient travels to Macau or Singapore and receives treatment there, the therapy is supplied and administered under the destination jurisdiction’s regulatory framework. The finished product is not being imported into Mainland China for administration.
This is why nearby jurisdictions can serve as lighthouse markets for advanced therapies. They can establish regulated clinical experience, specialist treatment capability and patient access near Mainland China without implying that a foreign approval automatically authorizes Mainland use.
The rules reviewed regulate drug products, collected biological materials and associated data. They do not appear to treat a patient returning after treatment as though the patient were importing an unadministered vial of the therapy.
This is a reasonable interpretation of the published rules, not an express statutory safe harbor. Treatment providers should still confirm any patient-specific travel, medical, follow-up and health-control requirements.
Travel also does not create an automatic right to receive treatment. The therapy must be lawfully available in the destination jurisdiction, and the treating hospital and physician must determine that the patient is eligible.
Does Chinese genetic material have to leave Mainland China?
Not necessarily. The answer depends heavily on the therapy model.
| Therapy model | Does collected Chinese-origin material leave Mainland China? | Principal regulatory issue |
|---|---|---|
| Donor-derived or allogeneic therapy administered in Macau or Singapore | Usually not, if the starting material comes from a non-Mainland donor or cell bank | The product and treatment must comply with the destination’s drug and clinical-use rules |
| Autologous therapy with cells collected in Mainland China and processed abroad | Yes | Clinical-purpose export, Customs, biosafety, data, logistics and destination requirements must be assessed |
| Autologous therapy with collection performed after the patient travels | No Mainland export of the collected sample | Collection, manufacture and administration are primarily governed by the destination jurisdiction |
| Research or clinical-trial samples sent abroad | Potentially | The PRC human genetic resources regime may require approval, filing or reporting |
China’s Human Genetic Resources Regulation defines human genetic resources materials broadly, including organs, tissues and cells containing human genes or genomes. It also distinguishes clinical diagnosis and treatment from research-focused HGR activities. (Human Genetic Resources Regulation)
Importantly, a 2025 National Health Commission clarification states that materials sent abroad for CAR-T treatment or genetic testing for clinical diagnosis and treatment do not require an HGR-material outbound administrative permit. (NHC HGR management clarification)
This corrects the overbroad claim that Chinese-origin cells can never leave Mainland China without an HGR export permit.
However, the clarification should not be stretched beyond its wording. It does not eliminate other potential requirements involving:
- Customs declaration and health quarantine;
- Biosafety and infectious-disease controls;
- Patient consent and personal-information protection;
- Cross-border transfer of genetic or clinical data;
- Cold-chain transportation;
- Chain of identity and chain of custody;
- Destination-country import and manufacturing rules; or
- Research, validation or product-development activities conducted alongside treatment.
A programme involving research or overseas product development requires a separate HGR assessment even if it also has a clinical-treatment component.
Can Mainland-Sourced Cord Blood Be Manufactured Overseas?
A Mainland-sourced cord-blood unit could, in principle, serve as the starting material for a patient-specific therapy manufactured overseas. China’s Special Blood Import and Export Measures permit cord-blood hematopoietic stem cells to be exported for a named patient when the unit is donated and matched, clinically urgent, and unavailable in the applicant’s country or region. An overseas bone-marrow registry or transplant medical institution must apply through the China Red Cross and Customs. The rules prohibit treating the unit as a sale, so any cost advantage should be described as a lower bank release or service fee—not as purchasing “cheaper cord blood.” Lower cost alone is not a legal basis for export.
The unresolved issue is overseas manufacturing. The rules contemplate stem cells sent abroad for transplantation but do not expressly address a unit sent to a commercial facility for substantial processing and then returned as a finished patient-specific therapy; a commercial manufacturer is also not one of the listed applicants. A potentially workable structure would have the treating transplant hospital request the unit for the named patient, with the overseas facility identified as an intermediate manufacturing site within the transplant plan. Whether that structure remains within the clinical-treatment pathway, rather than requiring separate human-genetic-resources authorization, should be confirmed in writing with the China Red Cross, Customs and the National Health Commission before a unit is selected or committed.
In practice, the simpler route may be to select an appropriately HLA-matched, manufacturer-qualified unit from an established overseas cord-blood bank, particularly where manufacturing already occurs outside Mainland China. No Chinese-origin starting material then needs to leave the Mainland, eliminating the PRC cord-blood export, HGR-classification and Red Cross/Customs questions described above. The regulatory analysis can instead focus on importing the finished patient-specific therapy through the applicable drug-access pathway, including the GBA pathway where the product and treating hospital qualify. This does not make import automatic, but it avoids putting the same treatment through both China’s donor-material export framework and its finished-drug import framework.
Could the Greater Bay Area pathway cover a cell therapy?
Potentially—but only after a product-specific assessment.
The Guangdong–Hong Kong–Macao Greater Bay Area pathway permits designated medical institutions in the nine Mainland GBA cities to apply for clinically urgent drugs already marketed in Hong Kong or Macau.
The governing Guangdong regulation does not contain an express categorical exclusion for cell therapies. It does, however, require:
- A designated Mainland medical institution;
- Demonstrated clinical urgency;
- A product-specific application and approval;
- Qualified importation and distribution arrangements;
- Appropriate clinical and technical capability;
- Risk-management and pharmacovigilance measures;
- Patient informed consent;
- Product traceability; and
- Use within the approved institution and clinical scope.
(GBA imported drugs and devices regulation)
The current application guidance took effect on August 8, 2026 and confirms that the designated medical institution—not the foreign manufacturer acting alone—is the applicant. (2026 GBA application guide)
The pathway is operating at meaningful scale. As of July 31, 2026, the Hong Kong Drug Office reported that 77 drugs and 95 medical devices had been approved for use through the programme across 71 designated medical institutions. (Hong Kong Drug Office)
None of this proves that a particular cell therapy qualifies. Advanced therapies can present unusually demanding requirements involving manufacturing consistency, hospital accreditation, specialist training, cold chain, chain of custody, long-term patient monitoring and adverse-event management.
A Hong Kong or Macau approval is therefore an entry condition for consideration under the GBA pathway—not automatic authorization for Mainland use.
Why Macau and Singapore matter
Macau and Singapore should be viewed as regulated access markets, not regulatory loopholes.
Macau has demonstrated that its regulatory framework can accommodate advanced cell therapies. In May 2024, Macau’s Pharmaceutical Administration Bureau announced Macau’s first approval of a CAR-T cell-therapy product and linked the development to the territory’s specialist healthcare and medical-tourism ambitions. (Macau Pharmaceutical Administration Bureau)
Singapore has a dedicated regulatory framework for cell, tissue and gene-therapy products. Class 2 products generally require registration, licensing and continuing safety controls.
Singapore also maintains a Special Access Route for certain unregistered Class 2 products, but it is narrow. HSA approval is required, the request must be made through qualified healthcare professionals and licensed institutions, and the pathway is intended for life-saving treatment where there is an unmet medical need and no suitable registered alternative.
Because HSA has not evaluated an unregistered product through the normal registration process, the requesting physician assumes responsibility for its use. Additional institutional, ethics, informed-consent, safety-reporting, traceability and record-retention requirements apply. (HSA cell, tissue and gene-therapy framework; HSA Special Access Route)
For manufacturers, a nearby jurisdiction may support:
- A compliant regional launch;
- Concentrated specialist expertise;
- Initial patient access;
- Institutional training and treatment experience;
- Real-world safety and outcomes evidence; and
- Longer-term planning for Mainland registration or GBA access.
However, every statement about availability must match the product’s actual approval status, the treating institution’s authorization and the rules applying to the individual patient.
A practical assessment framework
Before presenting any cross-border cell-therapy pathway, manufacturers and service providers should verify:
- Whether the material is a finished drug, starting material, diagnostic sample or research material;
- Whether the therapy is autologous or allogeneic;
- Where cell collection, processing and administration will occur;
- Whether any Chinese-origin cells, samples or associated genetic data will leave Mainland China;
- Whether the activity is solely clinical treatment or also involves research, testing or product development;
- The therapy’s approval or special-access status in the treatment jurisdiction;
- The treating hospital’s authorization and technical capability;
- Import, export, Customs and biosafety requirements;
- Shipping, cold-chain and chain-of-identity controls;
- Pharmacovigilance and long-term patient-monitoring obligations; and
- Whether a separate GBA application is legally and operationally viable.
Conclusion
The useful question is not simply, “Can human cells cross China’s border?” They can, in defined circumstances.
The better questions are:
What is crossing the border, for what purpose, under which regulatory classification, and where will the treatment occur?
For certain donor-derived therapies administered in Macau or Singapore, no collected Chinese-origin patient material may need to leave Mainland China at all.
For certain autologous clinical pathways, patient material may leave Mainland China without an HGR outbound permit under the NHC’s stated clinical-treatment exception, while remaining subject to other legal and operational controls.
For administration inside Mainland China, however, a foreign cell-therapy product still requires a valid Mainland access pathway. The physical ability to transport cells across the border is not enough.
That is the regulatory logic behind a credible lighthouse strategy: regulated patient access in a nearby jurisdiction, followed by evidence-led and product-specific planning for Mainland China.
Evaluating a Cell Therapy Access Strategy for Greater China?
ACA Pharma helps biopharma companies assess and execute product-specific access strategies across Macau, Hong Kong, Singapore and Mainland China.
Our capabilities include regulatory pathway assessment, local partner coordination, hospital engagement, cross-border logistics, cold-chain planning, GBA access preparation and commercial launch strategy.
If you are evaluating a cell, tissue or gene therapy for Greater China or Southeast Asia, contact ACA Pharma to discuss the appropriate market-entry pathway.
This article provides general regulatory information as of September 2026. It is not legal or medical advice and should not be used to determine the eligibility of a particular product, institution or patient. Requirements should be confirmed with qualified counsel and the relevant authorities for each proposed pathway.
